Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors

Antiviral Therapy

Volumn 14, Issue 8, 2009, Pages 1125-1137

  Nieto, Karen ^a   Kern, Andrea ^a   Leuchs, Barbara ^a   Gissmann, Lutz ^a   Müller, Martin ^a   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; FUSION GENE; GENE EXPRESSION; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; UTERINE CERVIX CANCER; VIRUS LIKE AGENT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEROTYPING; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 73449107465     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1469     Document Type: Article

References (45)

1. zur Hausen H (Editor). Infections Causing Human Cancer. Weinheim: Wiley-VCH 2006.
2. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109 Suppl 2:S15-S21.
3. Huh WK, Roden RB. The future of vaccines for cervical cancer. Gynecol Oncol 2008; 109:S48-S56.
4. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008; 26 Suppl 10:K62-K67.
5. Meisels A, Morin C (Editors). Modern Unterine Cytopathology. Chicago: ASCP Press 2007.
6. Muller M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology 1997; 234:93-111.
7. Schafer K, Muller M, Faath S, et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999; 81:881-888.
8. Ohlschlager P, Osen W, Dell K, et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003; 77:4635-4645.
9. Kaufmann AM, Nieland J, Schinz M, et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001; 92:285-293.
10. Kaufmann AM, Nieland JD, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007; 121:2794-2800.
11. Kuck D, Leder C, Kern A, et al. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly. Vaccine 2006; 24:2952-2965.
12. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008; 15:808-816.
13. Sun JY, Anand-Jawa V, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003; 10:964-976.
14. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21:583-593.
15. Xin KQ, Urabe M, Yang J, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 2001; 12:1047-1061.
16. Kuck D, Lau T, Leuchs B, et al. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 2006; 80:2621-2630.
17. Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007; 21:2135-2148.
18. Xin KQ, Ooki T, Mizukami H, et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther 2002; 13:1571-1581.
19. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78:6381-6388.
20. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5:285-297.
21. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003; 7:839-850.
22. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002; 99:11854-11859.
23. Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N. Production and purification of recombinant adeno-associated virus. Methods Enzymol 2000; 316:743-761.
24. Thones N, Muller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 2007; 369:375-388.
25. Stahl-Hennig C, Eisenblatter M, Jasny E, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009; 5:e1000373.
26. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 2008; 82:5472-5485.
27. Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol 1999; 236:215-236.
28. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70:3235-3241.
29. Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74:3852-3858.
30. Liqun Wang R, McLaughlin T, Cossette T, et al. Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol Ther 2009; 17:81-87.
31. Auricchio A, O'Connor E, Weiner D, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002; 110:499-504.
32. Xin KQ, Mizukami H, Urabe M, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 2006; 80:11899-11910.
33. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16:1073-1080.
34. Muller OJ, Schinkel S, Kleinschmidt JA, Katus HA, Bekeredjian R. Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats. Gene Ther 2008; 15:1558-1565.
35. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14:45-53.
36. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 2009; 17:294-301.
37. Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci U S A 2006; 103:12993-12998.
38. Halbert CL, Miller AD, McNamara S, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 2006; 17:440-447.
39. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505-517.
40. Yamamoto M, McGhee JR, Hagiwara Y, Otake S, Kiyono H. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand J Immunol 2001; 53:211-217.
41. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 2006; 80:9831-9836.
42. Di Pasquale G, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003; 9:1306-1312.
43. Wingender G, Garbi N, Schumak B, et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 2006; 36:12-20.
44. + T-cell responses in mice. J Virol 2007; 81:11840-11849.
45. Kim D, Gambhira R, Karanam B, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008; 26:351-360.